Bristol-Myers’ latest PD-1 win could pave the path to earlier use
Bristol Myers-Squibb ($BMY), a leader among companies at work…
GlaxoSmithKline takes another big swing at cancer drug R&D
Contrary to a common misperception in the industry, GlaxoSmithKline…
Virtual biotechs a hit with investors and, increasingly, buyers
Biotech venture capitalists have increasingly embraced the virtual…
Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO
A Dutch immuno-oncology player that has received venture funding…
Novartis tackles immuno-oncology with a $750M Aduro deal for new R&D group
Novartis ($NVS), a leader among companies using the immune system…